I think the data for 7977+RBV in GT2/3 are expected sooner than 7977+IFN+RBV in GT1. So unless, GILD decides to delay the filing (which would be irrational), the first NDA should be for either GT2/3 combined or GT2 alone depending on how the FDA feels about the GT3 SVR.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.